Henry Schein Medical President Dave McKinley Named Chief Commercial Officer; Karen Prange Named CEO of Global Animal Health & Medical Group
Henry Schein, Inc. (NASDAQ: HSIC), the world’s largest provider of health care products and services to office-based dental, animal health and medical practitioners, announced today that it has established two new senior executive roles to advance the Company’s commercial capabilities and drive growth opportunities.
Dave McKinley, currently President of the Henry Schein Medical Group, has been promoted to the newly created position of Chief Commercial Officer, and Karen Prange, Senior Vice President at Boston Scientific Corporation, will join Henry Schein as Executive Vice President and Chief Executive Officer, Global Animal Health & Medical Group.
“We have created these new positions at a time when market, technological and demographic forces are converging to create unique business opportunities for Henry Schein,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. Dave will apply his considerable talents to driving increased leverage across Henry Schein’s global platform, and Karen will bring to the Company her insight on managing fast-growing businesses in health care. Dave and Karen’s leadership will help the Company capitalize on the significant opportunities before us.”
Both Mr. McKinley and Ms. Prange will report to Mr. Bergman. Mr. McKinley is a member of the Company’s Executive Management Committee, which Ms. Prange will join.
Dave McKinley
Mr. McKinley, 63, also will serve as President of the Company’s newly formed Corporate Commercial Development Group, which will better coordinate and leverage the Company’s global brand and customer solutions across all of Henry Schein’s businesses. During his eight-year tenure as President of Henry Schein Medical, Mr. McKinley led the doubling of the group’s revenue and the integration of the Cardinal Health physician office business.
In his new role, Mr. McKinley will be responsible for global corporate marketing, working across the business to leverage Henry Schein’s brand; global product category management; technology initiatives, including customer solutions, e-commerce and business intelligence; and certain specialty businesses.
“Dave led the team that has been the driving force behind the extraordinary success of our Medical business, and he will bring his energy, intelligence, creativity and management excellence to enhancing our market presence,” Mr. Bergman said. “In his new role, Dave will use his deep knowledge of global trends in the health care marketplace.”
Before leading Henry Schein Medical, Mr. McKinley was President of Henry Schein Practice Solutions from 2006 to 2008, and President of Dental Prosthetic Solutions from 2005 to 2006. Prior to joining Henry Schein, Mr. McKinley served as the Group Executive for Olympus Medical North America, a market leader for medical and surgical instruments, endoscopes and imaging systems.
“As Henry Schein has grown and acquired numerous companies in the past decade, we have an extraordinary opportunity to further leverage our marketing and commercialization efforts and enhance our global network of health solutions,” said Mr. McKinley. “With a focused approach on the broader market opportunity, we believe we can drive additional benefit for the health care professionals who rely on us as well as the suppliers we are pleased to represent.”
Karen Prange
In her new position at Henry Schein, Ms. Prange, 52, will be responsible for Henry Schein’s global animal health and medical groups, as well as the Global Dental Surgical Group. At Boston Scientific, Ms. Prange is Senior Vice President and President, Urology and Pelvic Health. Focusing on new product launches, international expansion and acquisitions, she led the development of her business unit into a growth driver for Boston Scientific. Ms. Prange will join Henry Schein effective May 17, 2016.
Ms. Prange joined Boston Scientific in June of 2012. Prior to Boston Scientific, she spent 17 years at Johnson & Johnson in a series of increasingly responsible positions, including, in her last assignment, serving as General Manager of J&J’s Micrus Endovascular and Codman Neurovascular businesses. She is a graduate of the University of Florida.
“We are delighted to welcome Karen to Henry Schein,” said Mr. Bergman. “She has demonstrated throughout her career an exceptional ability to bring people together, manage change and grow businesses. Karen has a deep background in health care, a wealth of experience managing large, matrixed organizations, and the personal values that form the basis of our Team Schein culture.”
Ms. Prange will relocate from Boston and work out of Henry Schein’s headquarters in Melville, New York.
“I am excited to join Henry Schein, a company with a unique culture and a reputation for operational excellence and customer solutions known throughout the health care industry,” Ms. Prange said. “I look forward to building upon the success of this great company and doing my part to advance its key strategies at a time when the changing health care landscape affords organizations the opportunity to continue growth, as Henry Schein has demonstrated.”
About Henry Schein, Inc.
Henry Schein, Inc. (NASDAQ:HSIC) is the world’s largest provider of health care products and services to office-based dental, animal health and medical practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the S&P 500® and the NASDAQ 100® indexes, Henry Schein employs nearly 19,000 Team Schein Members and serves more than one million customers.
